Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pfizer tests new drug cocktail for Hard-to-Treat myeloma

NCT ID NCT05090566

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested elranatamab, a bispecific antibody that helps the immune system attack cancer cells, in combination with other drugs for people with multiple myeloma that had stopped responding to at least three prior treatments. The trial aimed to find the safest dose and see if the combinations could shrink tumors. However, the study was terminated early after enrolling 46 participants, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Elranatamab (a bispecific antibody) combined with either nirogacestat or lenalidomide plus dexamethasone
What this could lead to
If successful, this could point toward a new combination treatment for multiple myeloma that has stopped responding to standard therapies.
What could go wrong
The trial was terminated early with only 46 participants, so results are limited. It is still early-stage research, and the combinations may not prove safe or effective in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

46 people

The number who actually took part.

Started

Oct 2021

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy * Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody * Measurable disease defined by at least one of the following: 1. Serum M-protein \>/= 0.5 g/dL by SPEP 2. Urinary M-protein excretion \>/= 200 mg/24 hours by UPEP 3. Serum immunoglobulin FLC \>/= 10 mg/dL (\>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio * ECOG performance status 0 -1 * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade \</= 1 Exclusion Criteria: * Active plasma cell leukemia * Amyloidosis * Stem cell transplant with 12 weeks prior to enrollment, or active GVHD * POEMS syndrome * Any active uncontrolled bacterial, fungal, or viral infection * Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment * Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer) * Sub-Study A Only: Previous treatment with BCMA bispecific antibody * Sub-Study B Only: Previous treatment with BCMA directed therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Arthur J.E. Child Comprehensive Cancer Centre

    Calgary, Alberta, T2N 5G2, Canada

  • Banner Gateway Medical Center

    Gilbert, Arizona, 85234, United States

  • Banner Gateway Medical Pavilion

    Gilbert, Arizona, 85234, United States

  • Banner Health d.b.a. Banner MD Anderson Cancer Center

    Phoenix, Arizona, 85012, United States

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Beverly Hills Cancer Center

    Beverly Hills, California, 90211, United States

  • Cedars Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD

    Los Angeles, California, 90048, United States

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)

    Los Angeles, California, 90048, United States

  • Cedars-Sinai Tarzana

    Tarzana, California, 91356, United States

  • Clinical Research Advisors

    Encino, California, 91316, United States

  • Clinical Research Advisors

    Los Angeles, California, 90020, United States

  • Clinical Research Advisors

    Los Angeles, California, 90048, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, 21231, United States

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

    Coral Gables, Florida, 33146, United States

  • Sylvester Comprehensive Cancer Center- Deerfield Beach

    Deerfield Beach, Florida, 33442, United States

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21205, United States

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, K1H 8L6, Canada

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)

    Baltimore, Maryland, 21231, United States

  • UHealth Tower

    Miami, Florida, 33136, United States

  • University of Miami

    Coral Gables, Florida, 33146, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.